The purpose of this study was to prospectively evaluate the retinal and optic nerve changes in patients undergoing high-dose chemotherapy (HDC) followed by autologous hematopoietic progenitor cell support (AHPCS). One hundred and forty patients undergoing HDC and AHPCS underwent extensive pre-and post-transplant ophthalmologic evaluations for development of retinal microvascular complications. One hundred and ten patients received high-dose cyclophosphamide, cisplatin and BCNU; thirty received identical doses of cyclophosphamide and cisplatin, but received paclitaxel instead of BCNU. Thirty-four patients (24%) had retinal findings of either cotton wool spots (CWS) (n = 20) or retinal hemorrhages (n = 18) during follow-up, which ranged from 1 to 12 months. Ten (7%) of these patients, all of whom received BCNU, showed ocular toxicity characterized by CWS 1 to 4 months post transplant (n = 10); optic disc edema (n = 3); and variable vision loss associated with the onset of BCNU-induced pulmonary toxicity. Retinal and optic disc microvascular complications may occur after high-dose chemotherapy followed by AHPCS. The association of ischemic retinal lesions and/or optic disc edema with BCNU-induced pulmonary toxicity and the lack of ocular toxicity in patients that did not receive BCNU may suggest that BCNU is the etiologic agent.
hemorrhage, and optic disc edema associated with vision loss has been reported retrospectively in a small percentage of patients. 2 We noted similar findings of ocular toxicity with vision loss and ischemic microvasculopathy in the fundus of 6% of our patients after HDC with AHPCS. All of these patients also had BCNU-induced pulmonary toxicity, a known complication of BCNU-containing HDC regimens. 3 To study the real incidence, time course and outcome of this complication, we conducted a prospective clinical study in patients enrolled on HDC protocols at the University of Colorado Bone Marrow Transplant Program.
Materials and methods

Patients
Between December 1992 and August 1995, 140 patients undergoing HDC with AHPCS were followed prospectively with ophthalmologic examination prior to and after treatment with HDC and AHPCS at the University of Colorado Bone Marrow Transplant Program. All patients had a Southwest Oncology Group performance status of Ͻ2 and acceptable organ function pretransplant evaluated as follows: creatinine clearance Ͼ60 ml/min, left ventricular ejection fraction Ͼ45% measured by MUGA scan, singlebreath carbon monoxide diffusing capacity (DLCO) and forced expiratory volume in 1.0 s Ͼ60% of predicted, and bilirubin/SGOT/SGPT Ͻ2 times the upper limit of normal. No patient had a history of other systemic disease that might affect the retinal vasculature, such as diabetes or hypertension.
AHPC collection and HDC
Peripheral blood progenitor cells (PBPCs) were mobilized with granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA, USA) 10 g/kg/day subcutaneously for 7 consecutive days. Using the COBE Spectra apheresis machine (COBE BCT, Lakewood, CO, USA), patients underwent three to four sequential leukaphereses on days 5-8. Selected patients underwent a bone marrow harvest under general anesthesia. Hematopoietic progenitors were cryopreserved, stored, thawed, and reinfused on days −1, 0 and +1. Patients were admitted to the University of Colorado Bone Marrow Transplant Unit on day −7 (prior to HDC) and received vigorous intravenous hydration, suf- ficient to ensure a urinary output Ͼ250 ml/h and continuous bladder irrigation. All doses of chemotherapy were calculated, based on the actual patient body weight. If the actual weight was Ͼ20% over the ideal body weight, the average of the actual and ideal weight was used to calculate the body surface area. Beginning on day −6, cisplatin 165 mg/m 2 was administered as a 72-h continuous i.v. infusion. Cyclophosphamide 1875 mg/m 2 /day was administered as a 1-h infusion on days −6, −5 and −4, and BCNU 600 mg/m 2 was given over 2 h on day −3. Thirty of the140 patients were enrolled on a phase I dose-escalation protocol using paclitaxel in place of BCNU and identical doses of cisplatin and cyclophosphamide. Paclitaxel was given on day −7 at a dose ranging from 135 mg/m 2 to 825 mg/m 2 given as a 24-h i.v. infusion. Bone marrow and /or PBPCs were cryopreserved, stored, thawed, and reinfused as previously described.
Supportive care
Uniform supportive care measures were used. All patients received prochlorperazine, diphenhydramine, and lorazepam as antiemetic therapy, as well as ciprofloxacin and /l were switched to gentamycin, piperacillin and vancomycin. Antifungal treatment was added for patients who remained febrile 48 h after starting empiric intravenous antibiotics. Patients were transfused with irradiated blood products for a hematocrit Ͻ28% and platelet count Ͻ10 x 10 9 /l.
Pulmonary toxicity evaluation
Pulmonary toxicity was defined as either: (1) a decrease in DLCO of Ͼ25% when compared to pretreatment testing; (2) a lung biopsy showing histologic changes typical of acute lung chemotoxicity (type 2 pneumocyte hyperplasia or atypia, interstitial inflammation or fibrosis); or (3) new onset of shortness of breath and oxygen desaturation with moderate exercise. Patients who developed pulmonary toxicity were treated with oral prednisone 100 mg/day for 4 days, followed by a taper from 60 mg/day down to zero over 10 weeks.
Ophthalmologic evaluations
One examiner performed the ophthalmologic examinations on all patients enrolled on the study. These examinations included assessment of symptoms and past ocular history, best-corrected Snellen visual acuity for distance and near, Amsler grid testing, American Optical Hardy, Rand and Rittler (AOHRR) color plates, pupil function, extraocular motility, slit lamp examination, Goldman applanation tonometry, dilated ophthalmoscopic examination and photographs or fluorescein angiography as indicated. Automated visual fields (Humphrey Instruments central 24-2 threshold test) were obtained on selected patients with vision loss. All examination data, including the date of the visits, were entered on a standard form and subsequently entered into a computer database. Patients were referred for examination prior to HDC and were examined soon after HDC (usually 2-6 weeks after treatment). Follow-up examinations were then scheduled 3 and 6 months after treatment, and patients were examined as needed for onset of Table 3 Clinical characteristics of patients with ocular and pulmonary toxicity vision loss. Many patients traveled to the University of Colorado Health Sciences Center for treatment and could not return for follow-up. Some follow-up data was obtained from telephone interviews or correspondence with local ophthalmologists (four patients) or from telephone assessment of visual acuity (seven patients) with standard near acuity cards that were mailed to patients. 4 
Statistical analysis
The Fisher's exact test (two-sided) was used to evaluate for a correlation between the occurrence of ocular toxicity and the HDC regimen administered. We compared the incidence of pulmonary toxicity in the group of patients that received BCNU-containing HDC with the incidence in a group of patients that received identical doses of cisplatin and cyclophosphamide but paclitaxel instead of BCNU. The Fisher's exact test (two-sided) was also used to evaluate the association of ocular toxicity with pulmonary toxicity.
Results
The demographics, diagnoses, and chemotherapy regimens of patients who developed ocular toxicity are shown in Table 1 . There were 129 women and 11 men. One hundred and nineteen patients had breast cancer; 21 had other diagnoses such as ovarian cancer (n = 5), non-Hodgkin's lymphoma (n = 13), or Hodgkin's disease (n = 3). One hundred and ten patients received BCNU-containing HDC and 30 received paclitaxel-containing HDC. All patients received cyclophosphamide and cisplatin at identical doses and schedules. Ten patients in the BCNU group (7% of all patients; 9% of BCNU patients) developed ocular toxicity with variable degrees of vision loss and ischemic microvascular lesions of the retina and/or optic disc. Their average age was similar to patients who did not develop ocular toxicity and vision loss (mean age 45 vs 46, respectively). All patients with evidence of ocular toxicity were women with breast cancer, treated with the BCNU-containing regimen of HDC. These 10 patients also developed pulmonary toxicity.
The length of follow-up for patients with posterior segment findings (CWS, retinal hemorrhage or optic disc edema), pulmonary toxicity, and deceased patients is shown in Table 2 . Fifty-two (37%) patients had 6 months or more follow-up, 20 (14%) had at least 3 months, 46 (33%) had 2-6 weeks, and 23 (16%) had just one visit either pre-(n = 17) or post (n = 5) transplant. Thirty-one patients died during the follow-up period. Thirty-four patients (24%) showed some posterior segment findings with either CWS (n = 20) or intraretinal hemorrhage (n = 18). Twelve patients had CWS (n = 6) and/or retinal hemorrhage (n = 7) in the early post-transplant period, and 18 patients had these findings at later visits. Twenty-nine patients (21%) displayed pulmonary toxicity and were treated with oral prednisone. This complication was seen as early as 4 weeks and became more prevalent by 6 months after AHPCS (19 patients). Ten of these patients (34%) had variable levels of vision loss or disturbance. The clinical characteristics of these ten patients are shown in Table 3 . There was a significant association between ocular and pulmonary toxicity (P value Ͻ0.0001). No patients exhibited other systemic illnesses such as hypertension or diabetes. The onset of visual loss or disturbance ranged from 1 to 4 months after AHPCS. Associated pulmonary toxicity developed in four patients before, three simultaneously, and three after visual symptoms developed (range 1-4 weeks before or after symptoms). Baseline visual acuity ranged from 20/15 to 20/30. The worse visual acuity recorded ranged from 20/15 to 20/80. Seven patients experienced either return to baseline vision or sustained mild visual loss (within one line of baseline Snellen acuity). Three patients with more severe findings of optic nerve edema had nonreversible vision loss to 20/50 (patient 270), 20/60 (patient 208) and 20/80 (patient 163) in one eye. Six patients described paracentral scotomata on Amsler grid testing, and three patients showed definite color vision abnormalities on AOHRR color plate testing. Humphrey visual field testing showed paracentral scotomata in patient 289 and concentric constriction to within 10 degrees in patient 163. All 10 patients had CWS; eight had them bilaterally. One of three patients with bilateral optic nerve swelling showed an afferent pupillary defect that resolved. Fluorescein angiography was obtained on five patients and showed mid-to-late phase leakage from papillary, peripapillary, and parafoveal blood vessels. Capillary dropout associated with CWS was seen with leakage from surrounding telangiectatic vessels. Late optic nerve staining was seen in patients with disc edema. Clinical findings showed resolution and were non-progressive in any of the patients. Figures 1 to 9 demonstrate representative findings in four patients. We could not find a significant association between treatment received (BCNU vs non-BCNU containing HDC) and ocular toxicity (P value = 0.212) probably because of the small number of patients in the non-BCNU group.
Discussion
We report the first prospective and most thorough evaluation of ocular complications after HDC with AHPCS. Ophthalmologic findings after BMT have been well described. The use of TBI as part of the conditioning regimen and/or cyclosporin A for the prevention of GVHD have been reported to cause ischemic microvasculopathy in the ocular fundus. 5, 6 Vogler et al 7 reported ophthalmologic toxicities after autologous and allogeneic BMT for leukemia. They found symptomatic microvascular changes (CWS, capillary nonperfusion, macular edema and neovascularization) in the fundi of seven leukemic patients all of whom received TBI and high-dose cytosine arabinoside and most received prophylactic whole brain irradiation, as well as intrathecal methotrexate. The authors felt that these changes were consistent with radiation retinopathy, despite the fact that the doses of TBI were below the usual threshold for this complication (Ͻ3600 cGy). Gloor et al 8 reported three patients with visual loss and disseminated multifocal ischemic retinopathy with extensive cotton wool patches and retinal hemorrhages after allogeneic BMT. All patients received prophylactic brain irradiation, TBI and cyclosporin A. One hundred and twenty-seven patients were prospectively evaluated by Bernauer et al 5 for ophthalmologic changes after BMT. Thirteen of the patients (10%) who received allogeneic BMT, cyclosporin A and TBI developed microvascular changes in the fundus within 6 months of treatment. Findings included bilateral CWS in all patients, retinal hemorrhage in 11 patients, lipid deposits in three patients, and bilateral optic disc edema in three patients. Half of the patients with microvascular pathology complained of disturbed vision, and most of these patients had mildly decreased visual acuity. Fluorescein angiography showed capillary nonperfusion and adjacent intraretinal vascular abnormalities. Twenty-nine patients treated with TBI or cyclosporin A (but not both) showed no ischemic fundus lesions, suggesting a synergistic effect between cyclosporin A and TBI. Coskuncan et al 1 reported a 13% prevalence of posterior segment complications in 397 patients after BMT with cyclosporin A and TBI. Fourteen patients (4%) developed hemorrhagic complications, 17 (4%) developed CWS, and 11 (3%) developed optic disc edema; eight cases were presumed due to cyclosporin A exposure alone. None of our patients received cyclosporin A or TBI.
Systemic or regional chemotherapy alone has also been implicated in some cases of posterior segment microvasculopathy. Miller et al 9 reviewed the ocular and orbital toxicity of 11 patients treated with intracarotid cisplatin and BCNU. Significant loss of vision (worse than 20/60) was seen in the ipsilateral eye in eight of 11 patients 2-9 months after starting intracarotid chemotherapy. Characteristic changes included signs of retinal infarction, retinal periarteritis and periphlebitis in those patients treated with BCNU and by retinal pigment mottling and an extinguished ERG in patients treated with cisplatin alone or in combination with BCNU. Shingleton et al 10 retrospectively evaluated 50 patients for ocular toxicity who received systemic highdose intravenous BCNU. Two patients who received intravenous BCNU at a dose of 800 mg/m 2 developed bilateral CWS 4 weeks after treatment. One patient developed counting fingers vision with a fundus picture consistent with central retinal artery occlusion. The other patient expired with pulmonary toxicity confirmed on autopsy. Pathologic examination of the eyes showed cytoid bodies, elevated optic nerve heads, and thrombosed choroidal and retinal vessels. McLennan and Taylor 11 reported a case of bilateral optic neuroretinitis which occurred 10 days after a patient was treated with BCNU 50 mg, procarbazine, cyclophosphamide and prednisone.
Both cisplatin and paclitaxel are known to produce neurotoxicity. There have been rare reports of optic nerve or retinal toxicity with cisplatin. Wilding et al 12 reported 13 women who were treated with high cumulative doses of cisplatin (400-800 mg/m 2 ). Blurred vision, decreased color vision in three patients, and cone dysfunction on electroretinography in nine patients were documented. Irregular pigmentation in the macula was the only physical examination abnormality. The optic nerves appeared normal and visualevoked potentials were normal. Blurred vision improved, but color vision abnormalities persisted after discontinuation of cisplatin. Ostrow et al 13 treated with a similar high-dose chemotherapy regimen. They hypothesized that cisplatin was the etiologic agent, a correlation between cisplatin pharmacokinetics and the presence or absence of ocular complications. Both transient scintillating scotomata and visual impairment have been reported with paclitaxel. 15 In our experience, 34 of 140 patients treated with highdose cyclophosphamide, cisplatin, and BCNU developed some posterior segment findings with CWS, retinal hemorrhage, or optic disc edema. None of these patients had systemic conditions that might affect the retinal or optic disc vasculature, such as diabetes or hypertension. No patient exhibited other conditions which might cause disc swelling, such as optic neuritis, increased intracranial pressure, tumor infiltration or infection. The typical hematologic nadir (pancytopenia) occurring within several days after HDC in all patients may explain some of the ocular findings in the early post-transplant period. Ten of 140 patients, however, developed later onset (1-4 months) of microvascular retinal and/or optic nerve complications, well after the typical hematologic nadir had resolved. None of our patients were treated with TBI or received cyclosporin A. This syndrome may be different to the one previously described after allogeneic transplants using TBI and cyclosporin A. [5] [6] [7] All 10 patients who developed symptomatic ocular toxicity in the present series received cisplatin and BCNU, drugs known to cause ocular complications as described above. The fundus lesions appeared to be due to ischemic microvascular effects rather than direct retinal or optic nerve toxicity, making cisplatin less likely as the sole etiologic agent. All 10 patients that experienced ocular toxicity also developed BCNU-related pulmonary toxicity at or about the same time, and of the patients who developed pulmonary toxicity, 34% also developed ocular toxicity. Statistical analysis showed a correlation between the development of ocular and pulmonary toxicity suggesting a common etiology, although we did not find a statistically significant correlation between the HDC regimen administered and the occurrence of ocular toxicity. It is possible that an association would become evident with a larger number of patients in the non-BCNU group.
All patients with ocular toxicity showed resolution of their physical findings. In most cases, CWS and hemorrhages faded away within 2-3 months. In three patients (163, 208 and 270), visual acuity was significantly decreased and did not improve following resolution of fundus findings. All patients were treated with a 10-week course of oral prednisone with good resolution of pulmonary symptoms. While the resolution of both the pulmonary and ocular findings seemed to follow a similar time course, the role of steroid treatment in the evolution of ischemic microvascular retinal and optic disc lesions is uncertain. The occurrence of ocular toxicity in association with BCNU-related pulmonary toxicity may alert physicians to the possibility of this complication as the use of high-dose cyclophosphamide/ cisplatin/BCNU with AHPCS becomes a more commonly used treatment of various malignancies. 16 
